Bicara Therapeutics (BCAX) Enterprise Value (2023 - 2026)

Bicara Therapeutics' Enterprise Value history runs 4 years deep, the most recent figure standing at -$539.8 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 16.8% year-over-year to -$539.8 million in Q1 2026; TTM through Mar 2026 was -$539.8 million, a 16.8% decrease from a year earlier, with the FY2025 full-year figure at -$414.8 million, up 15.3% from the prior year.
• Enterprise Value slipped to -$539.8 million in Q1 2026 per BCAX's latest filing, from -$414.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$230.4 million in Q4 2023 and bottomed at -$539.8 million in Q1 2026.
• The 4-year median for Enterprise Value is -$449.4 million (2025), against an average of -$423.0 million.
• Across the five-year window, Enterprise Value sank 112.51% in 2024 and soared 44.28% in 2025, its largest moves.
• Year by year, Enterprise Value stood at -$230.4 million in 2023, then slumped by 112.51% to -$489.7 million in 2024, then gained by 15.3% to -$414.8 million in 2025, then slumped by 30.12% to -$539.8 million in 2026.
• Per Business Quant, the three latest BCAX Enterprise Value figures stand at -$539.8 million (Q1 2026), -$414.8 million (Q4 2025), and -$290.2 million (Q3 2025).